HPV阳性口咽癌经口机器人术后病理结外侵犯及其他不良特征风险
这项单中心回顾性队列研究纳入136例无明显临床结外侵犯的HPV阳性口咽鳞癌患者,均接受经口机器人手术及颈淋巴结清扫。80.1%患者至少有一项可能需辅助放疗的指征,19.9%存在病理结外侵犯,7.3%切缘阳性,25.0%有病理结外侵犯和/或切缘阳性。cN2b患者病理结外侵犯风险高于cN1-cN2a患者(OR 3.01,95%CI 1.14-8.10)。
要点
- 约四分之一经选择的HPV阳性口咽癌患者术后存在病理结外侵犯和/或切缘阳性。
- cN2b患者病理结外侵犯风险显著高于cN1-cN2a患者(OR 3.01,95%CI 1.14-8.10)。
- cN0-cN2a且无临床结外侵犯者可能适合首选手术以避免辅助化疗。
核心结论
- 在精心选择的无明显临床结外侵犯的HPV阳性口咽鳞癌患者中,约四分之一接受初次手术后存在病理结外侵犯和/或切缘阳性。
- AJCC-7 cT0-cT2 cN0-cN2b(尤其cN0-cN2a)且无临床结外侵犯征象者,若目标是避免辅助化疗和/或降低辅助放疗剂量/范围,可能适合首选手术治疗。
研究设计与样本
- 单中心学术三级医疗中心回顾性队列研究。
- 2012年3月1日至2021年3月1日共258例接受经口机器人手术的患者中,纳入136例连续、初治、HPV阳性口咽鳞癌、无 obvious 临床结外侵犯并接受根治性经口机器人手术及颈淋巴结清扫的患者。
- 手术指征包括非深部浸润性口咽肿瘤、软腭受累轻微、病理结外侵犯可能性低。
主要发现
- 136例患者中113例(83.1%)为男性,中位年龄63岁(四分位距55-70岁)。
- 109例(80.1%)至少有一项可能需辅助放疗的指征。
- 年龄、吸烟史、饮酒史和临床T分期与病理结外侵犯、切缘阳性、淋巴血管侵犯、神经周围侵犯或pN2及以上分期无关。
- 病理结外侵犯比例随临床N分期变化:cN0为0/16,cN1为8/48(16.7%),cN2a为3/23(13.0%),cN2b为16/45(35.6%)。
关键数值与推荐
- 根据2021年国家综合癌症网络指南,病理结外侵犯和切缘阳性是可能需辅助放化疗的指征。
- cN2b患者病理结外侵犯的比值比为3.01(95%CI 1.14-8.10),高于cN1-cN2a患者。
临床怎么用
- 对于无明显临床结外侵犯的HPV阳性口咽鳞癌患者,尤其是AJCC-7 cT0-cT2 cN0-cN2a者,若治疗目标为避免辅助化疗和/或降低辅助放疗剂量/范围,可考虑首选经口机器人手术加颈淋巴结清扫。
- 术前咨询时应告知患者术后约四分之一概率存在病理结外侵犯和/或切缘阳性,可能需要辅助治疗。
- cN2b患者术后病理结外侵犯风险较高,应充分评估手术与辅助治疗的利弊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Understanding patient-specific risk of adverse histopathologic findings after primary surgery for human papillomavirus (HPV)-positive oropharynx squamous cell carcinoma (OPSCC) may help guide patient consultations. OBJECTIVE: To determine the likelihood of adverse histopathologic features that may indicate adjuvant radiotherapy or chemoradiotherapy after primary surgery for HPV-positive OPSCC according to 2021 National Comprehensive Cancer Network guidelines. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was performed at a single academic tertiary care center. Of 258 patients who underwent transoral robotic surgery (TORS) from March 1, 2012, to March 1, 2021, 136 consecutive, treatment-naive patients with HPV-positive OPSCC without obvious clinical extranodal extension (ENE) who underwent definitive TORS and neck dissection were included in the analysis. Indications for surgical treatment included non-deeply infiltrative oropharynx tumors, minimal soft palate involvement, and low suspicion for pathologic ENE. EXPOSURES: Primary site TORS with neck dissection. MAIN OUTCOMES AND MEASURES: The primary outcomes were the adverse histopathologic features of pathologic ENE and positive surgical margins (PSM) that are indications for possible adjuvant chemoradiotherapy. Outcomes were compared among varying American Joint Committee on Cancer 7th edition (AJCC-7) T and N categories and patient clinical characteristics. RESULTS: Of the 136 patients included in the analysis (113 men [83.1%]; median age, 63 [interquartile range, 55-70] years), 109 (80.1%) had at least 1 indication for possible adjuvant radiotherapy. Twenty-seven patients (19.9%) had pathologic ENE and 10 (7.3%) had PSM. Thirty-four patients (25.0%) had pathologic ENE and/or PSM, whereas 3 (2.2%) had both. Age, smoking history, history of alcohol consumption, and clinical T category were not associated with pathologic ENE, PSM, lymphovascular invasion, perineural invasion, or pN2 category or greater. The proportion of pathologic ENE varied by clinical N category: 0 of 16 for cN0, 8 of 48 (16.7%) for cN1, 3 of 23 (13.0%) for cN2a, and 16 of 45 (35.6%) for cN2b. Compared with patients with cN1-cN2a disease, patients with cN2b disease had higher odds of pathologic ENE (odds ratio, 3.01; 95% CI, 1.14-8.10). Clinical and pathologic N category were concordant in 77 patients (56.6%), whereas 42 (30.9%) were upstaged and 17 (12.5%) were downstaged. CONCLUSIONS AND RELEVANCE: In this cohort study, approximately one-quarter of carefully selected patients with HPV-positive OPSCC without obvious clinical ENE undergoing primary surgery had pathologic ENE and/or PSM. Patients with AJCC-7 cT0-cT2 cN0-cN2b disease, especially cN0-cN2a, without signs of clinical ENE may represent appropriate candidates for primary surgery when avoidance of adjuvant chemotherapy and/or reduction of adjuvant radiotherapy dose/extent are the goals.
引用
- Zebolsky AL, George E, Gulati A, et al. Risk of Pathologic Extranodal Extension and Other Adverse Features After Transoral Robotic Surgery in Patients With HPV-Positive Oropharynx Cancer. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 34673904. doi:10.1001/jamaoto.2021.2777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。